For
UK
audiences
The professional's guide to product selection
The professional's guide to product selection
Mucolytic to facilitate expectoration by reducing sputum viscosity.
Nebusal 7%
Inhalation of nebulised solution, 4 ml, up to twice daily.
Nebulised hypertonic sodium chloride solution (3–7%) is used to mobilise lower respiratory tract secretions in mucous consolidation (e.g. cystic fibrosis).
Nebulised hypertonic sodium chloride solution (3%) is used for mild to moderate acute viral bronchiolitis in infants.
Recipients may benefit from the use of an inhaled bronchodilator before treatment with hypertonic sodium chloride to reduce the risk of temporary irritation, such as coughing, hoarseness, or reversible bronchoconstriction, which may occur.
Nebusal 7% nebuliser solution, sodium chloride 7%, 60 × 4 ml
Reduction of sputum viscosity.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic
Osmohale is used for an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness, a clinical feature of some respiratory conditions such as asthma.
Contraindications: Use with caution in renal impairment and to avoid in pregnancy. The Osmohale test should not be used in patients below 6 years of age due to their inability to provide reproducible spirometric measurements.
There is limited information on the use of Osmohale in patients 6-18 years of age therefore Osmohale is not recommended in this population.
Dose: See manufacturers’ instructions for more information. The test should be repeated until the patient has a positive response or 635 mg has been administered.
Mucolytic to facilitate expectoration by reducing sputum viscosity.
MucoClear 3%
Inhalation of nebulised solution, 4 ml, 2–4 times daily.
MucoClear 6%
Inhalation of nebulised solution, 4 ml, twice daily.
|
For Inhalation Use Only. |
|
| The recommended dose of Hypertonic saline solution for inhalation is one unit-dose vial 2 to 4 times a day, undiluted via a nebuliser. |
|
| PulmcoClear strength and dose should be individualised based on the status of the patient, age group and should be assessed at regular intervals of symptoms. |
|
Mucolytic to facilitate expectoration by reducing sputum viscosity.
4ml nebuliser solution up to twice daily undiluted. It can be used in conjunction with chest hygiene clearance which has been assessed in secondary care.